Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial

31 August 2024 (07:55 - 08:40)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Miss Nina Nouhravesh

Duke Clinical Research Institute, Durham (United States of America)

5 More presentations in this session

Presentation thumbnail

Nationwide analysis of in-hospital mortality and renal infarction trends following cardiac output assist device placement from 2017 to 2020

Doctor A. Balaji (Brooklyn, US)

Abstract Slides

Presentation thumbnail

Beating the clock: the impact of heart failure duration on CRT efficacy

Mr E. Grama (Barcelona, ES)

Abstract Slides

Presentation thumbnail

Optimizing aldosterone receptor antagonist therapy by sodium zirconium cyclosilicate in heart failure - OPRA-HF trial

Doctor C. Basic (Gothenburg, SE)

Abstract Slides

Presentation thumbnail

Understanding the benefits of renin-angiotensin-aldosterone system inhibitors and influence of hyperkalaemia on their prescription: a UK survey of healthcare professionals' views and practice

Doctor M. Wasef (Portsmouth, GB)

Abstract Slides Video

Presentation thumbnail

Echocardiographic evaluation of cardiac remodelling in a cohort of patients with heart failure and reduced ejection fraction treated with dapagliflozin

Doctor J. Bonini (Ferrara, IT)

Abstract Slides

Access the full session

Session thumbnail

Drugs, devices, and multidisciplinary care in heart failure

The Event

Event poster

ESC Congress 2024

31 August 2024 07:55 CET

You may be interested in

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

Congress Presentation

Audience Q&A

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources